Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hypertension drug enters phase 2 testing

NCT ID NCT07373613

First seen Feb 01, 2026 · Last updated May 23, 2026 · Updated 13 times

Summary

This study tests five different doses of a new drug called BR1400 in 330 adults with high blood pressure (essential hypertension). The goal is to see how well each dose lowers blood pressure and how safe it is over 8 weeks. Participants must have a certain blood pressure range and may or may not already be on blood pressure medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hanyang University Hospital

    Soeul, South Korea

    Contact

Conditions

Explore the condition pages connected to this study.